PMC:7228307 / 48411-48625 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"945","span":{"begin":107,"end":111},"obj":"Gene"},{"id":"946","span":{"begin":178,"end":182},"obj":"Gene"},{"id":"948","span":{"begin":209,"end":213},"obj":"Species"},{"id":"951","span":{"begin":48,"end":59},"obj":"Chemical"},{"id":"952","span":{"begin":65,"end":77},"obj":"Chemical"},{"id":"954","span":{"begin":194,"end":199},"obj":"Disease"}],"attributes":[{"id":"A945","pred":"tao:has_database_id","subj":"945","obj":"Gene:13866"},{"id":"A946","pred":"tao:has_database_id","subj":"946","obj":"Gene:13866"},{"id":"A948","pred":"tao:has_database_id","subj":"948","obj":"Tax:10090"},{"id":"A951","pred":"tao:has_database_id","subj":"951","obj":"MESH:D000068878"},{"id":"A952","pred":"tao:has_database_id","subj":"952","obj":"MESH:C000617981"},{"id":"A954","pred":"tao:has_database_id","subj":"954","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T391","span":{"begin":113,"end":118},"obj":"Body_part"}],"attributes":[{"id":"A391","pred":"fma_id","subj":"T391","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T90","span":{"begin":94,"end":98},"obj":"Disease"},{"id":"T91","span":{"begin":194,"end":199},"obj":"Disease"}],"attributes":[{"id":"A90","pred":"mondo_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/MONDO_0008734"},{"id":"A91","pred":"mondo_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"}],"text":"This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T832","span":{"begin":113,"end":127},"obj":"http://purl.obolibrary.org/obo/CL_0001034"}],"text":"This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T224","span":{"begin":113,"end":118},"obj":"http://purl.obolibrary.org/obo/CL_0000000"}],"text":"This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"945","span":{"begin":107,"end":111},"obj":"Gene"},{"id":"946","span":{"begin":178,"end":182},"obj":"Gene"},{"id":"948","span":{"begin":209,"end":213},"obj":"Species"},{"id":"951","span":{"begin":48,"end":59},"obj":"Chemical"},{"id":"952","span":{"begin":65,"end":77},"obj":"Chemical"},{"id":"954","span":{"begin":194,"end":199},"obj":"Disease"}],"attributes":[{"id":"A945","pred":"pubann:denotes","subj":"945","obj":"Gene:13866"},{"id":"A946","pred":"pubann:denotes","subj":"946","obj":"Gene:13866"},{"id":"A948","pred":"pubann:denotes","subj":"948","obj":"Tax:10090"},{"id":"A951","pred":"pubann:denotes","subj":"951","obj":"MESH:D000068878"},{"id":"A952","pred":"pubann:denotes","subj":"952","obj":"MESH:C000617981"},{"id":"A954","pred":"pubann:denotes","subj":"954","obj":"MESH:D009369"}],"text":"This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T46","span":{"begin":209,"end":213},"obj":"Species"}],"attributes":[{"id":"A46","pred":"ncbi_taxonomy_id","subj":"T46","obj":"NCBItxid:10095"},{"id":"A47","pred":"ncbi_taxonomy_id","subj":"T46","obj":"NCBItxid:10088"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T279","span":{"begin":0,"end":214},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T390","span":{"begin":113,"end":118},"obj":"Body_part"}],"attributes":[{"id":"A390","pred":"fma_id","subj":"T390","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice."}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T114","span":{"begin":94,"end":98},"obj":"http://purl.obolibrary.org/obo/GO_0001788"}],"text":"This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T39","span":{"begin":194,"end":199},"obj":"Disease"}],"attributes":[{"id":"A39","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"}],"text":"This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice."}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T35","span":{"begin":194,"end":199},"obj":"Phenotype"}],"attributes":[{"id":"A35","pred":"hp_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice."}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T114","span":{"begin":94,"end":98},"obj":"http://purl.obolibrary.org/obo/GO_0001788"}],"text":"This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T114","span":{"begin":94,"end":98},"obj":"http://purl.obolibrary.org/obo/GO_0001788"}],"text":"This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice."}

{"project":"LitCovid-sentences","denotations":[{"id":"T279","span":{"begin":0,"end":214},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T35","span":{"begin":194,"end":199},"obj":"Phenotype"}],"attributes":[{"id":"A35","pred":"hp_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice."}